Dendreon Crosses Fingers, Knocks on Wood, And Resubmits Provenge to FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
The Seattle prostate-cancer vaccine maker has filed again for approval two and a half years after the agency's contentious rejection.